A Clinical Trial to Assess the Pharmacokinetic Profile of Three Coenzyme Q10 Formulations in Heal… (NCT07255079) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Clinical Trial to Assess the Pharmacokinetic Profile of Three Coenzyme Q10 Formulations in Healthy Adults
Canada20 participantsStarted 2026-03
Plain-language summary
The goal of this clinical trial is to assess the pharmacokinetic profile of three Coenzyme Q10 formulations in healthy adults. The main question it aims to answer is:
What is the difference in the bioavailability of three Coenzyme Q10 (CoQ10) formulations as assessed by the incremental area-under-the-curve (AUC) from time 0 to the last measured timepoint (AUC0-72hr)?
Participants will be asked to consume three formulations of CoQ10 and will be evaluated for CoQ10 levels in blood, over a 71-day period.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females ≥ 18 years of age
✓. BMI between 18.5 to 29.9 Kg/m3, inclusive
✓. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
✓. Willingness to complete questionnaires and diaries associated with the study and complete all study requirements
✓. Agrees to maintain current lifestyle (diet, physical activity, medications, supplements, and sleep) as much as possible within study specific requirements throughout the study
✓. Provided voluntary, written, informed consent to participate in the study
✓. Healthy as determined by medical history and laboratory results as assessed by the Qualified Investigator (QI)
Exclusion criteria
✕. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
What they're measuring
1
Difference in the bioavailability of three Coenzyme Q10 (CoQ10) formulations as assessed by the incremental area-under-the-curve (AUC)
✕. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational products or comparator ingredients or inability to consume the standardized meals
✕. Following a specific diet (e.g. vegetarian, carnivore, paleo, vegan, etc.…)
✕. Unstable metabolic disease or chronic diseases as assessed by the QI
✕. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
✕. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI